We are a contract research organization
Offers cutting-edge research services and consultancy in the field of liver diseases
We provide tailored reliable solutions to our partners for successful strategic decision making
Previous
Next

The complete pre-clinical Solution

News

Latest BLB research published in the Journal of Hepatology

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology.

Barcelona Liver Bioservices announces collaboration with Surrozen

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with Surrozen, a biotech company developing tissue-specific antibodies that have the potential to regenerate tissue in situations of serious diseases.

Introducing the BarNa model®: BLB’s pre-clinical model of NASH

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease” in the peer-reviewed journal Cells.

Barcelona Liver Bioservices will be present at the ILC-EASL 2019

Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today its participation in the upcoming International Liver Congress (ILC) 2019 – the annual meeting of the European Association for the Study of the Liver (EASL) that will take place in Vienna in April 10-14th 2019.

Barcelona Liver Bioservices announces collaboration with Inventiva

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.

Barcelona Liver Bioservices announces partnership with BrudyLab

Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

BLB works toward helping our partners to accelerate the development of new chemical entities to treat human liver disease. We value talent, experience and dedication of each of our employees.

BLB seeks outstanding scientists, pharmacologists, biomedical engineers, computational biologists and business developers